Omeros Corporation's Stock Has Potential To Double This Year
By Biomed Group : We wanted to share some thoughts about O meros ( OMER ) , our top pick in the biotechnology industry, which fell from its long- term highs and is currently vastly undervalued. Moreover, Omeros has not yet been discovered by most investors, and has fundamental catalysts in place ...
Read the rest of this article on Healthcare Sector and Stocks Analysis from Seeking Alpha
Related Videos
-
Taking Another Look at Economic MoatsMorningstar recently upgraded several companies' moat ratings, and global equity research director Heather Brilliant explains why.
-
No Sign of Slowdown in Biotech M&AHigh levels of merger and acquisition activity will be the big theme of year for biotech , says Morningstar's Lauren Migliore.
-
Top Biotech Acquisition Candidates2011 was a relatively light year for biotech M&A, but it looks like activity is picking up in 2012.
-
Behind Morningstar's Economic Moat RatingMorningstar's Paul Larson outlines the five sources of wide economic moats, our research team's moat-rating process, and the performance of the Morningstar Wide Moat Focus Index.